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embolism (PE) in cancer patients. The hypercoagulability state of cancer patients poses several risk factors
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cancer. By using the most effective treatment for anticoagulation in cancer patients, health care professionals
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for prevention of recurrent venous thromboembolism and/or pulmonary embolism in cancer patients.
Study Design: Search of the most up to date medical literature to formulate a systematic review using 4
electronic databases and citations from other relevant articles.
Methods: The following databases were used to find the best research available: OVID-MEDLINE, CINAHL,
and PubMed in addition to reference lists from the included articles.
Results: Four randomized, controlled clinical trials of various sample sizes which addressed this specific issue
were reviewed; none of the studies were double-blinded and 2 out of 4 were terminated early due to poor
recruitment of subjects.
Conclusion: LMWH is the preferred anticoagulation for cancer patients because Warfarin shows higher rates
of recurrent VTE and higher risk for hemorrhage. More research is needed to solidify the evidence comparing
anticoagulation in cancer patients.
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Abstract   
 
Background:  A comparison of Low-Molecular Weight Heparin (LMWH) and oral 
anticoagulants is necessary in order to find the most effective prophylaxis for venous 
thromboembolism (VTE) and pulmonary embolism (PE) in cancer patients. The 
hypercoagulability state of cancer patients poses several risk factors and makes treatment 
and the potential complications more difficult to manage than in patients without cancer. 
By using the most effective treatment for anticoagulation in cancer patients, health care 
professionals can help reduce the risk of recurrent venous thromboembolism and/or 
pulmonary embolism while improving the quality of life.   
 
Hypothesis:  Low Molecular Weight Heparin will be the most effective and safest 
method of anticoagulation for prevention of recurrent venous thromboembolism and/or 
pulmonary embolism in cancer patients. 
 
Study Design:  Search of the most up to date medical literature to formulate a systematic 
review using 4 electronic databases and citations from other relevant articles 
 
Methods:  The following databases were used to find the best research available: OVID-
MEDLINE, CINAHL, and PubMed in addition to reference lists from the included 
articles. 
 
Results:  Four randomized, controlled clinical trials of various sample sizes which 
addressed this specific issue were reviewed; none of the studies were double-blinded and 
2 out of 4 were terminated early due to poor recruitment of subjects. 
 
Conclusion:  LMWH is the preferred anticoagulation for cancer patients because 
Warfarin shows higher rates of recurrent VTE and higher risk for hemorrhage.  More 
research is needed to solidify the evidence comparing anticoagulation in cancer patients. 
 
Keywords:  Anticoagulation, Neoplasms, Cancer patients, and Thromboembolism 
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Anticoagulation Treatment For Prevention Of Recurrent 
Thromboembolism In Patients With Cancer 
Introduction 
Thrombosis in cancer patients is considered to be the second leading cause of 
mortality. 1,2 The risk of cancer-associated thrombosis can be increased by chemotherapy, 
which can cause endothelial cell damage and is a predisposing factor for clotting.2, 3 
Cancer patients also have a higher rate of recurrent venous thromboembolic event (VTE), 
with the potential for a fatal pulmonary embolism (PE).4 These adverse events can be 
prevented with adequate anticoagulation, but the risks of treatment and prophylaxis can 
include hemorrhage and death. Cancer patients with venous thromboembolic events are 
also shown to have a poorer rate of survival when compared to cancer patients without 
thrombosis.3  
 Patients with cancer are in a state of hypercoagulability which predisposes them 
to fatal complications such as venous thromboembolism and pulmonary embolism.2,3 The 
exact mechanism for the hypercoagulability state of cancer patients is not fully 
understood, however, there are several proposed mechanisms to explain the increased 
risk of thromboembolism.5   
 One specific mechanism that explains the increased coagulability involves the 
production of cytokines by the tumor, which stimulate monocytes to express tissue 
factor.2 Tissue factor and cancer procoagulant can activate the coagulation process.3 
Previous research suggests that the tissue factor molecule, serves as a receptor for the 
activation of a specific coagulase factor (factor IIa), which stimulates activation of a 
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series of other coagulation factors. Tumor cells may also contribute to hypercoagulability 
because of their intrinsic production of procoagulant factors.3 
 Other non-specific explanations for the increased risk of thromboembolism in 
cancer patients include, the basic inflammatory response to tissue damage caused by the 
tumor, which leads to expression of tissue factor and activation of the coagulation 
process.2 The coagulation process also stimulates inflammation, which contributes to the 
state of hypercoagulability. 
 Extrinsic influences such as immobility, surgical procedures, insertion of vena 
caval filters, and chemotherapy also increase the risk of cancer-associated thrombosis.2 
Cancer patients, in general, tend to be more debilitated, which interferes with their 
mobility and ultimately contributes to venous stasis.    
 Although there are currently no specific guidelines for treatment of thrombosis 
associated with cancer patients, there are a variety of recommendations with different 
levels of supporting evidence (See Table 1).5, 6 The current treatment options include: 
Unfractionated Heparin (UFH), Low-Molecular-Weight Heparin (LMWH), and oral 
anticoagulation. Unfractionated heparin requires frequent monitoring and dosing 
adjustment because of its narrow therapeutic window and unpredictable dose responses.  
LMWH has shown less recurrence of venous thromboembolic events and bleeding 
events, but it is quite expensive and requires patients to do subcutaneous injections at 
least once daily. Other reasons why LMWH is preferred over other anticoagulation 
treatment is that it is not known to cause potentially hazardous drug interactions.6 The 
anticoagulation effect of LMWH is much more stable and does not require strict 
laboratory monitoring. Oral anticoagulants, like Warfarin, have the potential for drug 
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interactions and alterations of the anticoagulant effects. Antiemetics, steroids, and 
analgesics decrease Warfarin’s effects by weakening it, which alters the effectiveness of 
the medication.3,6 The INR is a lab value that measures the effectiveness of the oral 
anticoagulants. Use of Warfarin and other oral anticoagulants require frequent INR 
measurement through a venous blood sample and often numerous dosing adjustments. 
The frequent INR monitoring requires venous access which has a severe impact on the 
quality of life of cancer patients. A low INR indicates an increased risk of clotting, and 
the Warfarin dose should be increased. If the INR is high, there is an increased risk for 
bleeding and the dose of Warfarin should be lowered. The variation of INR can last for 
up to two weeks, which poses a particular difficulty in maintaining a therapeutic level of 
Warfarin. Azole antifungals and quinolone antibiotics can also disturb the concentration 
of Warfarin and change the INR, which has the potential to increase the bleeding risk.6 
Bleeding risk is also increased when using Warfarin with Cephalosporins, salicylates, and 
corticosteroids because of their ability to inhibit platelet aggregation factors.6 Another 
reason why Warfarin is suboptimal in the treatment of VTE in cancer patients is that 
treatment is sometimes interrupted due to thrombocytopenia that is induced by 
chemotherapy. The interruption in treatment results in INRs that are not within the 
therapeutic range, which increases risk of clotting or bleeding. Studies also reveal that 
cancer patients fall within a therapeutic INR range only 50% of the time.6 
 How can healthcare providers improve the quality of life for cancer patients by 
preventing the recurrence of venous thromboembolism without causing death from 
hemorrhage? 
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Purpose of the Study 
 The determination of the safest and most effective method of anticoagulation for 
cancer patients will help improve the quality of life and aid in reducing mortality from 
embolism. By reducing complications from venous stasis and minimizing the risk for 
bleeding, cancer patients can be freed from some of the concern regarding their cancer 
treatment, instead of having to deal with thromboembolism or PE while struggling to 
manage their cancer treatment. 
 The mechanism for the hypercoagulability state of cancer patients is poorly 
understood and there seem to be minimal definitive treatment strategies which would 
allow patients with cancer the chance for reduced complications and improvement in 
their quality of life. 
Methods 
 A comprehensive search for the best literature available was conducted on the 
following databases: OVID-MEDLINE, CINAHL, and PubMed. The search terms were a 
combination of: anticoagulation, anticoagulants, cancer patients, neoplasms, and 
thromboembolism. Data was limited to the last 9 years, English language, human 
subjects, and an additional search filter for randomized control trials. The interlibrary 
loan service was also utilized in order to gather more information that applies to the 
search terms. The reference list from the included articles was also used to glean 
additional information, with a limitation of beyond the year 2000. 
 The inclusion criteria were adults with cancer (any kind, any stage), 
anticoagulation comparisons, Low-Molecular-Weight Heparin (LMWH), oral 
anticoagulants, DVT (deep vein thrombosis) prophylaxis, 2001-2009, diagnosis with 
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current DVT and/or PE (pulmonary embolism). The exclusion criteria were adults 
without cancer, pediatrics with cancer, the use of aspirin, and data earlier than 2001. 
Results 
 A total of four articles were applicable to the question and search criteria (See 
Table 2). All four of the articles addressed the use of Low-Molecular-Weight Heparin in 
comparison with oral anticoagulation. One of the articles compared LMWH and 
Unfractionated Heparin with a Vitamin K antagonist. The remaining three articles 
compared various LMWH such as Enoxaparin or Dalteparin and Warfarin. The majority 
of the studies had small sample sizes, with the exception of the Lee et al study which had 
a sample size of 676 patients. 
 Lee et al compared LMWH with an oral anticoagulant for 6 months duration in 
cancer patients for prevention of recurrent thrombosis.7 Funding and the study drug were 
supplied by Pharmacia. 338 cancer patients with symptomatic proximal DVT, PE, or both 
were randomized to receive subcutaneous Dalteparin 200 IU/kg once daily for month 1. 
The remaining 5 months of Dalteparin were administered subcutaneously at a dose of 
approximately 150 IU/kg and dosing was based on the patient’s weight. Patients and/or 
family members were instructed to self-administer the subcutaneous injection from 
prefilled syringes once daily. Home care was arranged “if necessary.”7 
 The other 338 cancer patients received an initial dose of Dalteparin 200 IU/kg 
subcutaneously which was continued for five to seven days, until the INR was in 
therapeutic range. One of the oral anticoagulants, Warfarin or Acenocoumarol, was also 
started on day 1. Once INR was in therapeutic range, Dalteparin was discontinued and 
INR was monitored at least once every two weeks for the study duration. 
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 Lee et al were able to obtain a large sample size and complete their study (See 
Table 3). 27 patients in the Dalteparin group experienced DVT, PE, or both, compared to 
53 patients in the oral anticoagulant group. 20 of the patients in the oral anticoagulant 
group who experienced some kind of thrombotic event had an INR that was below 2.0 at 
the time of the event. 14 patients had DVT in the Dalteparin group and 37 had DVT in 
the oral anticoagulant group. In the Dalteparin group, there were a total of 13 patients 
who had PE, 5 of which were fatal. There were 16 patients in the oral anticoagulant group 
with pulmonary embolism; 7 were fatal PEs. Bleeding episodes occurred in 19 patients 
from the Dalteparin group. 2 of these patients had thrombocytopenia at the time. In the 
oral anticoagulant group, 12 patients experienced bleeding episodes with 6 having an 
INR greater than 3.0 at the time of the bleeding episode. A total of 130 patients in the 
Dalteparin group died and 136 patients in the oral anticoagulant group died during the six 
month study period. Progressive cancer was responsible for 90% of the deaths. One 
patient from the Dalteparin group died from hemoptysis secondary to metastatic lung 
cancer. Another patient with brain cancer from the Dalteparin group died from an 
intracranial bleed. A patient with prostate cancer in this group died from retroperitoneal 
bleeding. Another patient with lung cancer in the Dalteparin group died from pericardial 
bleeding. There were no fatal bleeding events in the oral anticoagulant group, however, 
two patients had intracranial bleeding, and two had retroperitoneal bleeding. They 
concluded that the recurrence of VTE in cancer patients was reduced when using long-
term LMWH. The difference in bleeding episodes among both groups was not 
statistically significant. There was no difference in mortality between the groups but the 
13 
 
researchers did suggest a survival benefit from using long-term LMWH compared to oral 
anticoagulation treatment. 
Hull et al examined long-term subcutaneous LMWH in comparison to initial IV 
heparin and long-term Warfarin for a total duration of three months.8 The study was 
funded by the Canadian Institutes of Health Research. All patients had cancer and 
proximal vein thrombosis. Hull et al were careful in their inclusion criteria to make sure 
none of the enrolled patients had any contraindications to treatment, a life-expectancy of 
less than three months, which would terminate prior to the end of the trial, and current 
treatment with anticoagulants. Risk factors for bleeding were also considered in the 
patient population. 100 patients were randomly assigned to receive subcutaneous 
Tinzaparin 175 IU/kg once daily. Patients and/or family members were instructed on 
proper administration techniques for the subcutaneous injection. The patients in this 
group had platelet counts at 14 and 21 days to screen for thrombocytopenia. The other 
100 patients were assigned to receive a bolus of 5000 units or 80 units/kg of IV 
Unfractionated Heparin and then a continuous infusion, which was based on the hospital 
protocol for Heparin administration. The patients randomized to this group were required 
to be hospitalized to ensure proper administration of the IV Heparin. Laboratory 
monitoring of activated partial thromboplastin time was also used to adjust the heparin 
dosing. Warfarin was started along with the heparin regimen at 5-10 mg daily and 
adjusted based on the therapeutic INR range of 2.0-3.0. UFH was discontinued on day 6 
as long as the INR was in therapeutic range and Warfarin was continued and titrated 
based on regular INR monitoring every 1-2 weeks until treatment was discontinued. 
Therapy was discontinued at 12 weeks, unless the primary care physician felt like 
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prolonged treatment was indicated. Use of acetylsalicylic acid was not allowed and drugs 
that inhibit platelet aggregation, specifically ticlopidine, sulfinpyrazone, dipyridamole, 
and nonsteroidal anti-inflammatory drugs, were “strongly discouraged.”8 
 Patients were instructed to return to clinic at 12 weeks to determine which 
patients had suffered from recurrent VTE and/or death (See Table 4). A separate 
committee that was not involved in patient care and unaware of the treatment interpreted 
all events “independently without knowledge of the other findings.”8 During the trial 
period of 3 months, none of the patients in the Enoxaparin group were lost to follow-up 
or withdrew consent. One patient withdrew consent at 3 months in the Heparin/Warfarin 
group but no patients were lost to follow-up or withdrew consent at one year. After one 
year from the start of the treatment, the patients or the primary care physicians were 
contacted to determine whether or not the subjects had recurrent venous 
thromboembolism and also to see if they were alive. One patient in the Enoxaparin group 
withdrew consent after one year. After 12 months of evaluation, 16 out of 100 from the 
Heparin/Warfarin group and 7 from the LMWH group experienced recurrent VTE. One 
patient had a subtherapeutic INR when they were diagnosed with the recurrent VTE. 
Bleeding episodes happened in 27 of the LMWH patients and 24 in the other group. Out 
of the 24 patients in the Warfarin group with bleeding episodes, 2 patients with major 
hemorrhage and 2 patients with minor bleeding episodes had elevated INR on the day of 
bleeding. 47 patients in the LMWH group and 47 patients in the Warfarin group died 
after one year and mortality was thought to be secondary to progression of cancer in the 
majority of the cases. 2 patients in the LMWH group and 7 patients in the Warfarin group 
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died suddenly; 3 of those deaths were confirmed pulmonary embolism and were all from 
the Warfarin group.   
The Hull et al study determined that long term LMWH offered improved efficacy 
in cancer patients for prevention of recurrent VTE without increased harm from bleeding 
episodes. The conclusion of Hull et al was that the cancer patients in the trial supported 
the outcome of improved efficacy with LMWH in prevention of recurrent VTE. 
 Meyer et al compared long-term Enoxaparin with Warfarin for a trial period of 
three months.9 The study was funded by Aventis. All 146 patients received an initial 
fixed dose of Enoxaparin 1.5mg/kg subcutaneously. 71 patients were randomized to 
receive Enoxaparin 1.5mg/kg subcutaneously for three months. Platelet count was also 
done twice per week for the first month, and then once per week until day 90. 75 patients 
were started on Enoxaparin 1.5 mg/kg subcutaneously and Warfarin 6-10 mg orally each 
day. At the point that the INR was within the therapeutic range the Enoxaparin was 
discontinued and the Warfarin was continued for the remainder of the three month period. 
The Warfarin dosage was adjusted based on INR monitoring with a therapeutic range of 
2.0-3.0. INR monitoring took place on a daily basis until a therapeutic level was 
maintained for two days then the INR was monitored on a weekly basis until day 90. If 
the physician felt like the INR needed closer monitoring, INR was measured more 
frequently in order to establish a therapeutic level. Once the trial period of three months 
was reached, the attending physician determined whether or not anticoagulation treatment 
was needed for each patient.     
 Meyer et al recruited 146 patients over a four year period to participate in the trial. 
The trial was terminated at the four year point by the data management committee 
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because the number of subjects was “not compatible with continuation of the study.” 9 
Out of the 146 study participants, eight patients were not able to be evaluated by the data 
committee because two of them were lost to follow-up, three withdrew consent, and three 
died. One patient who died was believed to have septic shock and another had acute onset 
of dyspnea and fever, which could have been related to a pulmonary embolism; neither 
patient had an autopsy. The other patient that died was believed to have a DVT, but the 
venous ultrasound was inconclusive.  
Among the remainder of patients that completed the Meyer et al study, 15 patients 
in the Warfarin group had major bleeding episodes or recurrent thromboembolism, 
compared to 7 patients in the Enoxaparin group (See Table 5). In the Warfarin group, 17 
patients died. Eight patients died in the Enoxaparin group. The six deaths that resulted 
from major hemorrhage were all assigned to the Warfarin group. The patients assigned to 
the Warfarin group had an INR within therapeutic range 41% of the time during 
treatment. There were no fatal bleeding events in the Enoxaparin group. Fourteen of the 
deaths were related to progression of cancer. Four patients died of sepsis and one died 
from aspiration pneumonia. Ten patients in the Warfarin group and 12 in the Enoxaparin 
group had progression of cancer (but did not die). At six month follow up, 121 patients 
were still alive. 29 patients in the Warfarin group died and 22 patients in the Enoxaparin 
group died. Progression of cancer was seen in 27 patients receiving Warfarin, compared 
to 24 patients in the Enoxaparin group. Minor bleeding episodes occurred in 9 patients 
receiving Warfarin and 5 patients who received Enoxaparin. Thrombocytopenia took 
place in 18 of the Warfarin patients and 16 of the Enoxaparin patients. The study 
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concluded that less patients in the Enoxaparin group experienced episodes of major 
hemorrhage, recurrent thromboembolism, and death.    
Deitcher et al compared long-term Enoxaparin (in two different dosages) with 
initial Enoxaparin and Warfarin for 180 days in cancer patients with acute, symptomatic 
venous thromboembolic events.10 The trial was sponsored by Aventis Pharmaceuticals. 
31 patients were randomized to receive Enoxaparin 1.0 mg/kg subcutaneously, twice per 
day for five days, then Enoxaparin 1.0 mg/kg daily for 175 days. The other group that 
received Enoxaparin alone consisted of 36 patients who took 1.0 mg/kg subcutaneously 
twice per day for five days, then 1.5 mg/kg subcutaneously daily for the remaining 175 
days. 34 patients were randomized to the Warfarin group and initially received 
Enoxaparin 1.0 mg/kg twice per day for a minimum of five days until a therapeutic INR 
was established. Oral Warfarin was started within 24 hours of the initial dose of 
Enoxaparin and continued for 180 days. 
 In the group that received Enoxaparin 1.5 mg/kg, 63.9% of the patients were 
female and 58.3% were 51 years or older. In the Enoxaparin 1.0 mg/kg group, 51.6% 
were female and 41.9% were 51 years or older. 47.1% of the Warfarin group was female 
and were younger, on average, than both of the Enoxaparin groups. 
 Thirteen patients in the Warfarin group had DVT and PE, compared to 7 patients 
in the Enoxaparin 1.0 mg/kg group and 10 patients in the 1.5 mg/kg group (See Table 6).  
Three patients in the Warfarin group had VTE during treatment, compared to 2 patients 
in each of the Enoxaparin groups. The number of non-fatal adverse events were 
distributed among the three groups, and occurred in 87.1% of patients overall. Among the 
Enoxaparin 1.0 mg/kg group and the Warfarin group, there were similarities between the 
18 
 
incidence of serious adverse events, with 51.6% in the Enoxaparin group and 50.0% in 
the Warfarin group. The highest number of serious adverse events was in the Enoxaparin 
1.5 mg/kg group with 63.9% of the group having at least one event.  
There were other differences among groups with specific cardiovascular events. 
The subjects with the highest rate of cardiovascular events were in the Enoxaparin 
groups; the Warfarin group had no patients who experienced any cardiovascular adverse 
events. Among those who experienced a serious adverse effect in other body systems, 
there were 2 patients in the Warfarin group and 1 patient in the Enoxaparin 1.0 mg/kg 
group whose events were considered “possibly or probably related to the study drug.”10 
Major hemorrhagic events happened in 4 patients in the Enoxaparin 1.5 mg/kg 
group, 2 in the Enoxaparin 1.0 mg/kg group, and 1 patient in the Warfarin group. There 
were a total of 33 deaths during 7 months of observation and follow up. 29 deaths were 
linked to progression of cancer, 1 in the Enoxaparin 1.0 mg/kg group died of presumed 
PE, 1 in the Enoxaparin 1.0 mg/kg group died of VTE, 1 in the Enoxaparin 1.5 mg/kg 
group died of heart failure, and 1 died of cardiac arrest in the Warfarin group.  
There were 12 patients eliminated from the study because of death prior to the end 
of the study period; the remainder of the patients that died completed 180 days of 
treatment. The highest rate of withdrawal was 58.3 % of patients from the Enoxaparin 1.5 
mg/kg group and was primarily due to death or adverse events. The lowest rate of 
discontinuation was in the Enoxaparin 1.0 mg/kg group at 41.9% and was because these 
patients reached the study end point and had recurrent VTE or major hemorrhage. 
Compliance rates among the groups were an overall average of 95%. Overall 
compliance was lowest in the Warfarin group at an average of 90.1% compared to 97.9% 
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in the Enoxaparin 1.0 mg/kg group and 97.0% in the Enoxaparin 1.5 mg/kg group. 
Among all groups, 91.1% of the patients took 81-100% of the study medication and 6 
patients (5.9%) were compliant with less than 81% of the study drug. The patients in the 
Warfarin group had the lowest rate of medication compliance with a rate of 50-100%. 
The Enoxaparin 1.0 mg/kg group had the best compliance rate of 82-100%. 
 Despite early termination of the Deitcher et al study due to poor recruitment of 
patients, the researchers were able to conclude that Enoxaparin was more effective than 
Warfarin at decreasing the incidence of recurrent venous thromboembolism in cancer 
patients. There were no differences among the groups for significant bleeding events. 
Deitcher et al concluded that 180 days of treatment with LMWH is at least as effective 
and safe as using Warfarin for long-term treatment of recurrent VTE in cancer patients.  
Discussion 
 All four studies concluded that LMWH, in comparison with oral anticoagulants, 
was the most effective treatment for prevention of recurrent VTE, PE, or both, while also 
being more effective at decreasing the risk of bleeding, including fatal hemorrhage. Lack 
of power in the studies conducted by Meyer et al, Hull et al, and Deitcher et al was 
obvious in the small sample sizes and unclear, poorly defined results and discussion. 
There were no dietary restrictions in the studies, which has the potential to 
interfere with INR measurement and skew Warfarin treatment. Certain medications could 
also alter the therapeutic range of INR and are important considerations in these trials. 
The Hull et al study was the only study to mention their restriction of acetylsalicylic acid 
for all of the patients in the study. They also discouraged the use of certain other 
medications which could alter the effect of the anticoagulants. 
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 In addition to the small sample size and early termination, Meyer et al had other 
weaknesses that impacted their data. First of all, all of the patients included in the trial 
(except two) received anticoagulation prior to randomization, which seems to contradict 
the idea of randomization. Although the INR measurement was done regularly, the INR 
for the majority of the study participants was only in the therapeutic range for 41% of the 
treatment time.9 If the INR is not in therapeutic range, this could be at least partially 
responsible for the higher bleeding rate noted in the Warfarin group. Also, the dosing of 
Warfarin was managed by the investigator of the trial or the primary care provider, 
instead of being managed by a coagulation clinic, which tends to have more consistency. 
Other possibilities for the skewed outcome of the Meyer et al study is that their patients 
had poor hepatic functioning due to chemotherapy and/or were taking a medication which 
caused a drug interaction and inaccurate INR measurements. 
 There are minimal large trials with the latest and most up to date information.  
Results of the current trials can often overlap within the same trial, which distracts the 
reader from the lack of power in the study. Percentages also seem to demonstrate lack of 
power in the current available studies and take away from statistically significant data. It 
is extremely important to recruit as many candidates for collecting data as possible to 
account for drop-out rates, poor medication compliance, and inconclusive follow-up. 
 The previous systematic review that was conducted by Akl et al, published in 
2008 investigated patients with and without cancer, whereas this systematic review 
includes patients with cancer. The Akl et al systematic review also contains older 
research.11 Despite differences in articles used for the reviews, the conclusions are the 
same. There is need for more trials with better design and a higher patient recruitment in 
21 
 
order to confirm that LMWH is superior to oral anticoagulation for prevention of 
recurrent VTE in cancer patients. 
 Further study on anticoagulation in cancer patients is important in order to 
establish clear guidelines. Recommendations for stronger research include only 
investigating patients with cancer and comparing LMWH and oral anticoagulants. 
Although cost of the study drugs may be a limiting factor, the cost of complications 
related to recurrent VTE in cancer patients is far more of a concern and should not limit 
further research or proper treatment. LMWH may be more expensive to use, but 
definitive results in its effectiveness may outweigh the cost of treatment, especially in 
cases where it can prevent a fatal outcome. Dietary and medication restrictions are also 
important parts of the investigation in order to accurately account for any potential 
medication or food interactions which may skew data.  Larger study groups are perhaps 
one of the most important factors in the data collection as demonstrated by the early 
termination in 2 of the 4 studies because of poor recruitment of subjects. 
Conclusion/Recommendations 
 The most current available data on anticoagulation in cancer patients for 
prevention of recurrent VTE indicates that LMWH is more effective and efficient in 
comparison to oral anticoagulation therapy. The benefits of using LMWH outweigh the 
risks but cost is also a factor. LMWH is significantly more expensive and requires daily 
subcutaneous injections but does not require the strict monitoring of INR and variable 
dosing that Warfarin requires. The quality of life for cancer patients is an important 
concern and LMWH seems to be the best option because there is no need for frequent 
venous access to measure INR.   
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 Many other medications also alter the INR values and metabolism of Warfarin, 
which poses more of a challenge when using Warfarin for long-term treatment of VTE. 
Although the data lacks strength, LMWH is suggested to have benefit in survival of 
cancer patients, especially when compared to Warfarin, whether it is because of 
prevention of recurrent VTE or simply has less incidence of fatal hemorrhage. 
23 
 
TABLE 1.  Current Recommended guidelines for use of LMWH in cancer patients with 
VTE 6 
Group Recommendation for use of a LMWH Definition of the category of evidence 
   
ACCP Use during the first 3 to 6 months of long-
term anticoagulant therapy (grade 1A).  
anticoagulant therapy should continue 
indefinitely or until the cancer is resolved 
(grade 1C). 
1A: strong recommendation; can apply 
to most patients in most 
circumstances without reservation 
1C: intermediate-strength 
recommendation; may change when 
stronger evidence is available 
ASHP LMWH therapy for the treatment of acute 
DVT is as safe and effective as traditional 
therapy with unfractionated heparin in 
appropriate adult outpatients. 
Positions statement; level of evidence 
is not applicable 
AIOM Initial treatment with weight-adjusted dose 
LMWH.  In patients with severe renal failure 
(creatinine clearance <25-30 mL), suggest IV 
UFH or LMWH with anti-Xa monitoring (grade 
3B).  in patients with active cancer, long-term 
LMWH until cancer disease is resolved (grade 
3C). 
3B: evidence is obtained from well-
designed, quasi-experimental studies 
such as non-randomized, controlled 
single group, prepost, cohort, time, or 
matched case-control studies; findings 
are generally consistent 
 
3C: evidence is obtained from well-
designed, quasi-experimental studies 
such as non-randomized, controlled 
single group, prepost, cohort, time, or 
matched case-control studies; findings 
are inconsistent 
NCCN Monotherapy (without Warfarin) is 
recommended (up to 6 months) treatment of 
proximal DVT or PE, and prevention of 
recurrent VTE in patients with advanced or 
metastatic cancer who do not have 
contraindications to anticoagulation. (grade 
2A) 
2A: There is uniform NCCN consensus, 
based on lower level evidence 
including clinical experience, that the 
recommendation is appropriate. 
ACCP, American College of Chest Physicians; AIOM, Italian Association of Medical Oncology; ASHP, 
American Society of Health-System Pharmacists; NCCN, National Comprehensive Cancer Network 
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TABLE 2.  Summary of the four reviewed articles  
 
Reference Methods Intervention Participants Outcomes Notes 
Lee 2003 Randomized, 
open-label, 
multicenter 
trial 
LMWH vs 
coumarin 
derivative 
Cancer 
patients with 
acute, 
symptomatic 
DVT, PE, or 
both 
Higher 
probability of 
recurrent VTE 
in the oral 
anticoagulant 
group 
Funding 
provided by 
Pharmacia 
Hull 2006 Randomized, 
open-label 
multi-center 
trial 
LMWH vs 
Vitamin K 
antagonists 
Cancer 
patients with 
acute, 
symptomatic 
proximal vein 
thrombosis 
LMWH is more 
effective than 
Vitamin K 
antagonists for 
prevention of 
recurrent VTE 
Funded by 
Canadian 
Institutes of 
Health Research 
Meyer 
2002 
Randomized, 
open-label 
multicentral 
trial 
Enoxaparin 
vs Warfarin 
Cancer 
patients with 
either PE or  
VTE 
Warfarin is 
associated with 
high bleeding 
rate; LMWH 
may be as 
effective for 
anti-coagulation 
and safer 
Funded by 
Aventis 
pharmaceuticals 
Deitcher 
2006 
Randomized, 
open-label 
multidose 
active 
comparator 
parallel trial 
Enoxaparin 
vs Warfarin 
Adults with 
active 
malignancy 
Lower incidence 
of VTE with 
Enoxaparin 
alone than with 
Warfarin 
Sponsored by 
Aventis 
pharmaceuticals 
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TABLE 3.  Primary Efficacy Outcome Events in the Lee et al study7 
 
Event Dalteparin 
(N=336) 
Oral 
Anticoagulation 
(N=336) 
   
Deep-vein thrombosis alone 14 37 
Nonfatal pulmonary embolism 8 9 
Fatal pulmonary embolism 5 7 
Total 27 53 
 
 
 
 
TABLE 4. Primary Efficacy Outcome Events at 3 and 12 months in the Hull et al study8 
Event Tinzaparin 
N=100 n 
UFH and vitamin K 
antagonist 
N=100 n  
Difference, (95% CI) P-value 
New episodes of venous 
thromboembolism 
At 3 months 
 
 
     6  
 
 
   10  
 
     
    -4.0 (-12.0 to 4.1) 
 
 
 
 
At 12 months 7  
 
16  -9.0 (-21.7 to -0.7) .044 
Bleeding complications 
during 3 months 
treatment interval 
    
All 27  24  -3.0 (-9.1 to 15.1)  
Major 7  7  0.0 (-7.1 to 7.1)  
Minor 
 
 
Death 
20  17 3.0 (-7.8 to 13.8) 
 
 
At 3 months 20 19 1.0 (-10.2 to 11.9)  
At 12 months     47    47      0.0 (-14.6 to 13.2)  
 
 
 
 
26 
 
TABLE 5. Primary Efficacy Outcome Events in the Meyer et al study9 
Event (at 3 months) Enoxaparin group 
n=75 (%) 
Warfarin group 
n=71 (%) 
P 
value 
Major outcome event ( major bleeding or VTE )      7 (10.5)    15 (21.1)   P=.09 
    
Major hemorrhage 5  12  
Fatal hemorrhage 0 6   
Deaths 8 (11.3) 17 (22.7) P=.07 
 
 
 
 
 
TABLE 6. Summary of Adverse Events in the Deitcher et al study10 
Adverse Event Enoxaparin 1.0 
mg/kg, n=31 (%) 
Enoxaparin 1.5 
mg/kg, n=36 (%) 
Warfarin, 
n=34 (%) 
Total, n = 
101 (%) 
Nonserious 27 (87.1) 32 (88.9) 29 (85.3) 88 (87.1) 
Treatment-related, nonserious 3 (9.7) 6 (16.7) 8 (23.5) 17 (16.8) 
Discontinued due to 
nonserious adverse event 
1 (3.2) 0 (0.0) 2 (5.9) 3 (3.0) 
Serious adverse event 16 (51.6) 23 (63.9) 17 (50.0) 56 (55.4) 
Minor hemorrhage event 19 (61.3) 20 (55.6) 17 (50.0) 56 (55.4) 
Major hemorrhage event 2 (6.5) 4 (11.1) 1 (2.9) 7 (6.9) 
Died 7 (22.6) 15 (41.7) 11 (32.4) 33 (32.7) 
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